查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2072253

活細胞封裝市場（第二版）：依製造技術類型、封裝方法、封裝材料類型、應用、治療領域、支付方式及主要地區分類－趨勢與預測（至2035年）

Live Cell Encapsulation Market (2nd Edition) by Type of Manufacturing Technique, Method of Encapsulation, Type of Encapsulation Material, Application Area, Therapeutic Area, Type of Payment and Key Geographical Regions - Trends and Forecast, Till 2035
出版日期: | 出版商: Roots Analysis | 英文 215 Pages | 商品交期: 最快1-2個工作天內

價格

活細胞封裝市場概覽

預計到 2035 年，活細胞封裝市場規模將以 12.1% 的複合年成長率成長，從今年的 6.42 億美元成長到 2035 年的 17.87 億美元。

活細胞封裝市場－成長與趨勢

細胞包封是一種先進的生物工程技術，它將活細胞包裹在半透性聚合物膜或水凝膠基質（例如藻酸鹽）內。這些系統允許氧氣、營養物質、生長因子和治療性蛋白質的選擇性交換，同時保護細胞免受宿主免疫反應的攻擊。這使得細胞能夠在無需長期免疫抑制的情況下持續存活並發揮功能。

這項技術最早於1930年代開始研究，如今已發展成為一個用途廣泛的平台，可用於組織工程、再生醫學、控釋藥物和細胞療法。它在慢性疾病的治療方面具有巨大潛力，例如透過封裝胰島移植來治療第1型糖尿病，以及治療神經系統疾病和代謝性疾病。

在活細胞封裝技術中，特別著重於維持封裝細胞的生物活性、增殖能力和治療性分泌能力。這引發了人們對該技術在再生醫學（旨在遞送靶向幹細胞和前驅細胞）、癌症免疫療法和神經保護等新應用領域的濃厚興趣。

鑑於該技術具有許多治療和臨床優勢，包括增強免疫保護、透過持續分泌生物分子延長治療效果、提高細胞活力以及減少對免疫抑制療法的依賴，預計活細胞封裝市場在預測期內將實現顯著成長。這些優勢預計將推動活細胞封裝市場在預測期內的成長。

成長要素－市場擴張的策略促進因素

活細胞封裝市場的成長主要受糖尿病、癌症和自體免疫疾病等慢性病盛行率上升的驅動。這顯著增加了對能夠改善治療效果和支持組織再生的先進療法的需求。為了滿足這一日益成長的臨床需求，公共和私營部門對再生醫學和細胞療法研發的大量投資正在加速可擴展且具有臨床應用價值的封裝技術的開發。此外，生物材料、微流體和奈米封裝技術的不斷進步正在提高細胞活力、精確性、穩定性和生物相容性，從而增強封裝細胞系統在藥物遞送、組織工程和再生醫學領域的應用。這些因素共同作用，使活細胞封裝技術成為滿足未被滿足的醫療需求的關鍵基礎技術，並推動其在全球醫療保健市場的廣泛應用。

市場挑戰－阻礙進展的主要障礙

儘管活細胞封裝技術具有巨大的治療潛力，但其市場仍面臨許多挑戰，這些挑戰可能會阻礙其廣泛應用和商業化。其中一個主要限制因素是維持封裝系統內細胞的長期活力、穩定性和功能，特別是在生理條件下，其複雜性。此外，生物相容性、免疫反應、營養和氧氣擴散不足以及治療效果的差異性等限制因素，仍是臨床成功的技術障礙。該市場還面臨大規模生產、製程標準化和高昂生產成本等挑戰，這些挑戰將限制擴充性和商業性可行性。此外，細胞療法的嚴格監管要求、漫長的核准週期以及缺乏長期臨床數據，也為市場參與企業帶來了進一步的障礙。這些科學、營運和監管方面的挑戰，綜合起來，可能會影響活細胞封裝技術在整個醫療保健產業的創新速度和廣泛應用。

活細胞封裝市場－關鍵洞察

本報告詳細分析了活細胞封裝市場的現狀，並指出了該行業潛在的成長機會。報告的主要發現包括：

  • 細胞封裝技術能夠將活細胞精確地輸送到生物相容性微環境中，使其功能得以長期維持，並有望在先進的治療領域中得到應用。
活細胞封裝市場-IMG1
  • 目前市面上約有 25 種活細胞封裝技術，旨在保護移植細胞免受免疫系統攻擊，並促進治療性生物分子的持續和局部遞送。
  • 近55%的技術採用了微膠囊化技術，凸顯了其在產業中的主導地位。尤其值得一提的是，其中40%的技術主要用於封裝細胞，以治療包括第1型糖尿病在內的代謝性疾病。
活細胞封裝市場-IMG2
  • 大部分協議涉及封裝細胞療法的研究和開發，用於治療第 1 型糖尿病、黃斑部毛細血管擴張症和其他慢性疾病等疾病。
  • 近 50% 的投資是在過去兩年內完成的，創業投資已成為最主要的資金籌措模式，佔這些交易的 30%（A 輪融資）。
  • 近年來，超過20%的細胞封裝技術相關專利已公開。這顯示人們對利用封裝細胞療法治療各種疾病的興趣日益濃厚。
  • 大部分津貼並非用於小型企業創新研究/小型企業技術轉移（SBIR/STTR）專案。其中，研究津貼（R系列）佔比相對較大，而第5類撥款則成為主要津貼類別。
  • 受慢性病日益普遍和技術快速進步的推動，活細胞封裝市場預計將在未來一段時間內保持穩定成長。
活細胞封裝市場-IMG3
  • 目前，抗體細分市場佔了大部分市場佔有率，這得益於單株抗體的廣泛應用，單株抗體在癌症、自體免疫疾病和感染疾病的標靶治療中發揮著至關重要的作用。
  • 今年，碳水化合物細分市場預計將佔大部分市場佔有率，因為澱粉、蔗糖和葡萄糖廣泛用於藥物製劑中，作為生技藥品的穩定劑和填充劑。
  • 受美國個人化醫療日益普及的推動，預計活細胞封裝市場在預測期內將以更高的複合年成長率成長。

活細胞封裝市場

市場規模和機會分析是根據以下參數進行細分的：

透過封裝法

  • 微膠囊化
  • 大分子膠囊化
  • 奈米封裝

依製造技術類型

  • 靜電滴落法
  • 簡單的滴漏
  • 同軸氣流法
  • 使用旋轉圓盤進行噴塗
  • 其他製造技術

依材料類型

  • 基於藻酸鹽的微膠囊
  • 幾丁聚醣
  • 醫用塑膠
  • 二氧化矽
  • 纖維素水凝膠
  • 紅血球

用途別

  • 藥物輸送
  • 免疫保護
  • 益生菌和機能性食品
  • 其他

按治療區域

  • 代謝性疾病
  • 腫瘤性疾病
  • 神經系統疾病
  • 眼科疾病
  • 循環系統疾病
  • 腎臟疾病
  • 其他疾病

透過付款方式

  • 預付款
  • 里程碑付款

按主要區域

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 法國
  • 荷蘭
  • 英國
  • 比利時
  • 亞太地區
  • 日本
  • 新加坡

活細胞封裝市場－主要細分市場

依製造技術分類的市場佔有率：靜電噴墨技術佔最大佔有率。

今年，靜電滴注技術預計將佔活細胞封裝市場最大的佔有率（約40%）。此技術的領先優勢源自於其在封裝過程中能夠保持較高的細胞活力，最大限度地降低剪切應力，並產生粒徑分佈窄且極為均勻的微膠囊。此外，該技術高度符合現有的監管要求，進一步推動了其在臨床和研究應用中的廣泛應用。

尤其值得注意的是，同軸氣流細分市場預計在預測期內將實現最快的成長速度，達到 13.0%。

按封裝類型分類的市場佔有率：預計微膠囊封裝領域將繼續引領市場。

目前，微膠囊化技術預計將佔活細胞封裝市場最大的佔有率（約60%），並且預計在預測期內將以11.8%的較高複合年成長率進一步成長。此細分市場的成長主要得益於其在治療領域的廣泛應用、實現藥物控釋的能力以及與多種聚合物材料的高度相容性。

按封裝材料分類的市場佔有率：預計藻酸鹽基微膠囊細分市場將產生最大的收入。

今年，基於藻酸鹽的微膠囊預計將佔活細胞封裝市場最大的佔有率（約45%）。這主要歸功於該材料的高生物相容性、低免疫抗原性、成本效益以及在生理條件下誘導離子凝膠化的能力，從而維持細胞活力。此外，受市場對耐用、擴充性且應用特定的封裝材料需求不斷成長的推動，醫用塑膠領域預計將在預測期內實現最快成長，複合年成長率將達到13.0%。

按應用領域分類的市場佔有率：藥物傳輸領域佔市場佔有率最大。

今年，藥物遞送領域預計將佔活細胞封裝市場最大的佔有率，並在預測期內以12.3%的複合年成長率成長。此領域的成長主要歸功於封裝的活細胞能夠實現治療分子的可控、持續釋放，從而提高療效、減少給藥頻率並改善患者依從性。

按治療領域分類的市場佔有率：代謝性疾病領域是市場的主要驅動力。

預計今年代謝性疾病領域將佔最大的市場佔有率（約42%），並在預測期內以12.3%的複合年成長率成長。這一成長主要受全球代謝性疾病負擔日益加重（尤其是第1型糖尿病）以及旨在改善疾病長期管理效果的包涵體胰島細胞和BETA細胞療法的持續進展所驅動。

區域分析

北美－最大的區域市場

市場預測顯示，北美今年將佔活細胞封裝市場最大佔有率（約50%）。該地區的主導地位歸功於其完善的醫療和研究基礎設施、強勁的公共和私人投資，以及美國國立衛生研究院（NIH）和美國食品藥物管理局（FDA）等機構提供的強力的政府支持。

此外，眾多領先的生物技術和製藥公司的存在，加上有利於細胞療法的法規結構以及對個人化和再生醫學日益成長的關注，繼續推動該地區的市場成長。

亞太地區：新興高成長地區

亞太地區活細胞封裝市場預計將呈現最高成長速度，到2035年年複合成長率（CAGR）將達到11.84%。這一成長主要得益於醫療基礎設施的不斷改進、成本效益高的臨床試驗環境、對先進細胞療法日益成長的需求，以及醫療專業人員和患者意識提升的提高。此外，中國、日本、印度和韓國等主要市場的策略研發措施預計將在預測期內進一步鞏固該地區的市場地位。

活細胞封裝市場主要公司示例

  • Algorae Pharmaceuticals
  • AltuCell
  • Austrianova
  • BIO INX
  • Encellin
  • Likarda
  • Sphere Bio
  • TreeFrog Therapeutics

第一次調查總結

本研究中提出的觀點和見解是基於與多位相關人員的討論。本研究報告包含與以下產業相關人員的詳細訪談記錄：

  • 美國一家小型企業的創辦人兼執行長
  • 以色列一家小規模公司的前任執行長

此外，本市場報告還包含與以下第三方進行的討論記錄：

  • 一家美國中型公司的執行長
  • 美國一家大型公司的腫瘤內科副總裁
  • 一家美國中型公司的執行長

活細胞封裝市場：研究範圍

  • 市場規模和機會分析：本報告對活細胞封裝市場進行了詳細分析，重點關注關鍵市場細分，例如 [A] 製造技術類型，[B] 封裝材料類型，[C] 應用，[D] 支付方式，[E] 關鍵地區。
  • 活細胞封裝市場概覽：除了對活細胞封裝的整體市場狀況進行詳細評估外，本報告還包括有關幾個相關參數的信息，例如 [A] 封裝方法類型，[B] 給藥途徑，[C] 應用，[D] 使用的材料類型，[E] 治療領域，[F] 治療類型，[G] 成立年份，[H] 公司規模。
  • 技術競爭分析：這是基於各種相關參數（例如 [A] 公司的優勢和 [B] 其產品組合的優勢）對各種活細胞封裝技術進行的詳細技術競爭分析。
  • 公司簡介：我們提供總部位於北美、歐洲和亞太地區的領先公司的詳細簡介，依據多個參數，例如 [A] 成立年份、[B] 總部所在地、[C]產品系列、[D] 近期發展以及 [E] 資訊驅動的未來展望。
  • 夥伴關係與合作分析：本分析聚焦在該領域相關人員之間建立的夥伴關係。這包括對各種夥伴關係模式的概述，以及基於[A]合作年份、[B]合作類型和[C]區域分析的夥伴關係詳細分析。
  • 資金籌措與投資分析：對活細胞封裝領域的投資進行詳細評估。這包括種子輪融資、創業投資、IPO資金籌措、二次性發行、津貼和獎勵以及其他股權和債務資金籌措，並基於多個參數，例如[A]投資年份，[B]投資金額，[C]資金籌措類型，[D]地區，[E]最活躍的參與者（按資金籌措數量和投資金額計），以及[F]主要投資者（按資金籌措數量計）。
  • 專利分析是根據以下關鍵參數進行的：[A] 專利類型，[B] 公開年份，[C] 申請年份，[D] 已授權專利和專利申請數量，[E] 專利管轄區，[F] CPC 代碼，[G] 專利已過年限，[H] 申請人類型，以及 [I] 個人專利持有人（就其知識產權組合的規模。
  • 津貼分析：本節根據以下幾個因素對活細胞包埋領域獲得的資助進行了詳細分析，包括 [A]津貼授予年份，[B] 資助津貼，[C]津貼機構/中心，[D]津貼目的，[E]津貼申請類型，以及 [F] 最受歡迎的 NIH 部門。
  • 市場影響分析：本部分詳細分析可能影響市場成長的因素，包括關鍵市場促進因素、潛在限制因素、新興機會以及該行業現有挑戰的識別和分析。

目錄

第1章：序言

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章摘要整理

第6章：引言

  • 細胞封裝概述
  • 封裝類型
  • 封裝方法
  • 細胞封裝的應用
  • 細胞封裝技術的優勢
  • 未來趨勢

第7章 市場狀況

  • 章節概要
  • 活細胞封裝技術：市場現狀

第8章：技術競爭力分析

  • 章節概要
  • 調查方法和關鍵參數
  • 評分標準
  • Peer Group概覽
  • 活細胞封裝技術：技術競爭力分析

第9章：公司簡介

  • 章節概要
  • Algorae Pharmaceuticals
  • Altucell
  • Austrianova
  • BIO INX
  • Encellin
  • Likarda
  • Sphere Bio
  • TreeFrog Therapeutics

第10章夥伴關係與合作

第11章資金籌措和投資

  • 章節概要
  • 資金籌措模式
  • 資金籌措生命週期分析
  • 投資案例研究：風險與回報
  • 活細胞封裝：資金籌措和投資清單

第12章 專利分析

  • 章節概要
  • 研究範圍和調查方法
  • 活細胞封裝市場：專利分析
  • 活細胞封裝：專利基準分析
  • 專利評估與分析

第13章：津貼分析

  • 章節概要
  • 津貼類型
  • 津貼申請類型
  • 需要考慮的重要因素
  • 津貼階段
  • 調查方法和關鍵參數
  • 活細胞封裝：津貼分析

第14章 市場影響分析：促進因素、阻礙因素、機會與挑戰

  • 章節概要
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場挑戰
  • 結論

第15章：全球活細胞封裝市場

第16章：活細胞封裝市場（依製造技術類型分類）

第17章：活細胞封裝市場（依封裝方式分類）

第18章：活細胞封裝市場（依封裝材料類型）

第19章：活細胞封裝市場（依應用領域分類）

第20章：活細胞封裝市場（依治療領域分類）

第21章：活細胞封裝市場（依支付方式分類）

第22章：活細胞封裝市場（依地區分類）

第23章：活細胞封裝市場機會分析：北美

第24章：活細胞封裝市場機會分析：歐洲

第25章：活細胞封裝市場機會分析：亞太地區

第26章：波特的五力模型

  • 章節概要
  • 調查方法和先決條件
  • 關鍵參數
  • 結論

第27章 結論

第28章：高階主管洞見

第29章附錄一：表格形式數據

第30章 附錄二：公司與組織列表

Product Code: RA100532

Live Cell Encapsulation Market: Overview

As per Roots Analysis, the live cell encapsulation market is estimated to grow from USD 642 million in the current year to USD 1,787 million by 2035, at a CAGR of 12.1% during the forecast period, till 2035.

Live Cell Encapsulation Market: Growth and Trends

Live cell encapsulation is an advanced bioengineering technique in which viable cells are enclosed within semi-permeable polymeric membranes or hydrogel matrices (e.g., alginate). These systems allow selective exchange of oxygen, nutrients, growth factors, and therapeutic proteins while shielding cells from host immune responses, thereby supporting sustained cell viability and function without long-term immunosuppression.

First explored in the 1930s, the technology has evolved into a versatile platform for tissue engineering, regenerative medicine, controlled drug delivery, and cell-based therapies. It has shown strong potential in managing chronic conditions such as type 1 diabetes via encapsulated pancreatic islet transplantation, as well as neurological and metabolic disorders.

In live cell encapsulation, the focus is specifically on preserving the biological activity, proliferative capacity, and therapeutic secretion of living cells post-encapsulation. This has driven growing interest in regenerative medicine for targeted stem and progenitor cell delivery, and in emerging applications such as cancer immunotherapy and neuroprotection.

Given the multiple therapeutic and clinical advantages associated with the technology, including enhanced immune protection, prolonged therapeutic efficacy through sustained biomolecule secretion, improved cell survival, and reduced dependency on immunosuppressive treatments, the live cell encapsulation market is anticipated to witness significant growth during the forecast period. These advantages are expected to drive the growth of the live cell encapsulation market during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The growth of the live cell encapsulation market is primarily driven by the rising prevalence of chronic diseases, including diabetes, cancer, and autoimmune disorders, which has significantly increased the demand for advanced therapeutic approaches capable of improving treatment efficacy and supporting tissue regeneration. In response to this growing clinical need, substantial public and private sector investments in regenerative medicine and cell-based therapy research have accelerated the development of scalable and clinically viable encapsulation technologies. Additionally, continuous advancements in biomaterials, microfluidics, and nanoencapsulation technologies have enhanced cell viability, precision, stability, and biocompatibility, thereby strengthening the applicability of encapsulated cell systems across drug delivery, tissue engineering, and regenerative medicine. Collectively, these factors are positioning live cell encapsulation as a critical enabling technology for addressing unmet medical needs and driving its expanding adoption across the global healthcare market.

Market Challenges: Critical Barriers Impeding Progress

Despite its significant therapeutic potential, the live cell encapsulation market faces several challenges that may hinder its widespread adoption and commercialization. One of the primary constraints is the complexity associated with maintaining long-term cell viability, stability, and functionality within encapsulation systems, particularly under physiological conditions. Additionally, limitations related to biocompatibility, immune response, insufficient nutrient and oxygen diffusion, and inconsistent therapeutic output continue to pose technical barriers to clinical success. The market also faces challenges associated with large-scale manufacturing, process standardization, and high production costs, which can restrict scalability and commercial feasibility. Further, stringent regulatory requirements for cell-based therapies, coupled with lengthy approval timelines and limited long-term clinical data, create additional hurdles for market participants. Collectively, these scientific, operational, and regulatory challenges may impact the pace of innovation and broader adoption of live cell encapsulation technologies across the healthcare industry.

Live Cell Encapsulation Market: Key Insights

The report delves into the current state of the live cell encapsulation market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Live cell encapsulation technologies enable the precise delivery and prolonged functionality of living cells within biocompatible microenvironments for advanced therapeutic applications.
Live Cell Encapsulation Market - IMG1
  • The current landscape comprises of ~25 live cell encapsulation technologies designed to provide immune protection for transplanted cells, facilitating the sustained, localized delivery of therapeutic biomolecules.
  • Close to 55% of the technologies use microencapsulation method, highlighting its dominance in the industry; notably, 40% of these technologies encapsulate cells targeting metabolic disorders, primarily type 1 diabetes.
Live Cell Encapsulation Market - IMG2
  • Majority of the agreements have been inked for the research and development of encapsulated cell therapies to target indications, such as type 1 diabetes, macular telangiectasia, and other chronic conditions.
  • Close to 50% of the investments have been made in the last two years; notably venture capital emerged as the most prominent funding model, with Series A rounds accounting for 30% of its transactions.
  • More than 20% of the patents related to cell encapsulation technologies have been published in a recent year; this is indicative of the rising focus on encapsulated cell therapies for the treatment of various disorders.
  • Majority of the grants were awarded for Non-SBIR / STTR purposes; of these, a relatively larger proportion were research grants (R series) with type 5 emerging as the primary grants category.
  • Given the rising prevalence of chronic diseases, coupled with rapid technological advancements, the live cell encapsulation market is anticipated to witness a steady growth in the foreseen future.
Live Cell Encapsulation Market - IMG3
  • Currently, majority of the market share is captured by antibodies subsegment owing to the widespread use of monoclonal antibodies, which play a vital role in targeted therapies for cancer, autoimmune, and infectious diseases.
  • Carbohydrates sub-segment is estimated to capture most of the market share in the current year, due to the extensive use of starch, sucrose, and dextrose in drug formulations as stabilizers and bulking agents for biologics.
  • Driven by the growing adoption of personalized medicine in the US, the live cell encapsulation market is poised to grow at a higher CAGR over the forecast period.

Live Cell Encapsulation Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Method of Encapsulation

  • Microencapsulation
  • Macroencapsulation
  • Nanoencapsulation

By Type of Manufacturing Technique

  • Electrostatic Dripping
  • Simple Dripping
  • Coaxial Airflow
  • Rotating Disk Atomization
  • Other Manufacturing Techniques

By Type of Encapsulation Material

  • Alginate-based Microcapsules
  • Chitosan
  • Medical-grade Plastics
  • Silica
  • Cellulose Hydrogels
  • Red Blood Cells

By Application Area

  • Drug Delivery
  • Immune Protection
  • Probiotics and Functional Food
  • Others

By Therapeutic Area

  • Metabolic Disorders
  • Oncological Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Cardiovascular Disorders
  • Nephrological Disorders
  • Other Disorders

By Type of Payment

  • Upfront Payments
  • Milestone Payments

By Key Geographical Regions

  • North America
  • US
  • Canada
  • Europe
  • France
  • Netherlands
  • UK
  • Belgium
  • Asia-Pacific
  • Japan
  • Singapore

Live Cell Encapsulation Market: Key Segments

Market Share by Manufacturing Technique: Electrostatic Dripping Segment Holds the Largest Share

In the current year, the electrostatic dripping segment is expected to account for the largest share (~40%) of the live cell encapsulation market. The segment's dominance can be attributed to its capability to produce highly uniform microcapsules with narrow size distribution while maintaining high cell viability and minimizing shear stress during the encapsulation process. Additionally, the technique demonstrates strong compatibility with established regulatory requirements, further supporting its widespread adoption across clinical and research applications.

It is worth highlighting that the coaxial airflow segment is anticipated to witness the fastest growth, with a projected CAGR of 13.0% during the forecast period.

Market Share by Encapsulation Type: Microencapsulation Segment to Maintain Market Leadership

Currently, the microencapsulation segment is projected to capture the highest share (~60%) of the live cell encapsulation market and is further anticipated to expand at a comparatively higher CAGR of 11.8% over the forecast period. The segment's growth is primarily supported by its broad applicability across therapeutic areas, ability to enable controlled therapeutic release, and enhanced compatibility with a wide range of polymeric materials.

Market Share by Encapsulation Material: Alginate-based Microcapsules Segment to Generate Highest Revenue

Alginate-based microcapsules are expected to account for the largest share (~45%) of the live cell encapsulation market in the current year. This can be attributed to the material's high biocompatibility, low immunogenicity, cost-effectiveness, and ability to undergo ionic gelation under physiological conditions, thereby preserving cell viability. In addition, the medical-grade plastics segment is anticipated to witness the fastest growth during the forecast period, with a projected CAGR of 13.0%, driven by increasing demand for durable, scalable, and application-specific encapsulation materials.

Market Share by Application: Drug Delivery Segment to Dominate the Market

In the current year, the drug delivery segment is expected to hold the largest share of the live cell encapsulation market and is projected to grow at a CAGR of 12.3% during the forecast period. The segment's growth is primarily driven by the ability of encapsulated live cells to provide controlled and sustained release of therapeutic molecules, thereby enhancing treatment efficacy, reducing dosing frequency, and improving patient compliance.

Market Share by Therapeutic Area: Metabolic Disorders Segment to Lead the Market

The metabolic disorders segment is anticipated to account for the highest market share (~42%) in the current year and is expected to witness a CAGR of 12.3% during the forecast period. This growth is largely driven by the increasing global burden of metabolic diseases, particularly type 1 diabetes, alongside ongoing advancements in encapsulated islet cell and beta-cell therapies aimed at improving long-term disease management outcomes.

Regional Analysis

North America: Largest Regional Market

According to market projections, North America is expected to capture the largest share (~50%) of the live cell encapsulation market in the current year. The region's leadership can be attributed to its well-established healthcare and research infrastructure, robust public-private investments, and strong government support through organizations such as the NIH and FDA.

Additionally, the presence of a large number of leading biotechnology and pharmaceutical companies, coupled with favorable regulatory frameworks for cell-based therapies and increasing focus on personalized and regenerative medicine, continues to support regional market growth.

Asia-Pacific: Emerging High-Growth Region

The Asia-Pacific live cell encapsulation market is projected to witness the highest growth rate, with an anticipated CAGR of 11.84% through 2035. This growth is primarily driven by expanding healthcare infrastructure, cost-efficient clinical trial environments, increasing demand for advanced cell-based therapies, and growing awareness among healthcare providers and patients. Furthermore, strategic research and development initiatives across key markets, including China, Japan, India, and South Korea, are expected to further strengthen the region's market position during the forecast period.

Example Players in Live Cell Encapsulation Market

  • Algorae Pharmaceuticals
  • AltuCell
  • Austrianova
  • BIO INX
  • Encellin
  • Likarda
  • Sphere Bio
  • TreeFrog Therapeutics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Founder and Chief Executive Officer, Small Company, US
  • Former Chief Executive Officer, Small Company, Israel

In addition, the market report includes transcripts of the following other third-party discussions:

  • Chief Executive Officer, Mid-sized Company, US
  • Vice President, Medical Oncology, Large Company, US
  • Chief Executive Officer, Mid-sized Company, US

Live Cell Encapsulation Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the live cell encapsulation market, focusing on key market segments, including [A] type of manufacturing technique, [B] type of encapsulation material, [C] application area, [D] type of payment, [E] and key geographical regions.
  • Live Cell Encapsulation Market Landscape: A detailed assessment of the overall live cell encapsulation market landscape, along with information on several relevant parameters, such as [A] type of encapsulation method, [B] route of administration, [C] application area, [D] type of material used, [E] therapeutic area, [F] type of therapy, [G] year of establishment [H] company size, and [I] location of headquarters.
  • Technology Competitiveness Analysis: An in-depth technology competitiveness analysis of various live cell encapsulation technologies based on various relevant parameters, such as [A] company strength, and [B] portfolio strength.
  • Company Profiles: In-depth profiles of key companies based in North America, Europe and Asia-Pacific based on several parameters such as [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Partnerships and Collaborations Analysis: An analysis of the partnerships that have been inked by stakeholders engaged in this domain. It includes a brief description of various partnership models and includes a detailed analysis of partnerships based on [A] year of partnership, [B] type of partnership, and [C] geographical analysis.
  • Funding and Investment Analysis: A detailed evaluation of the investments made in the the live cell encapsulation domain, encompassing seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing, based on several parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] geography, [E] most active players (in terms of number of funding instances and amount invested) and [F] leading investors (in terms of number of funding instances).
  • Patent Analysis: A detailed analysis of the patents that have been filed / granted based on important parameters such as, [A] type of patent, [B] publication year, [C] application year, [D] number of granted patents and patent applications, [E] patent jurisdiction, [F] CPC symbols, [G] patent age, [H] type of applicant, and [I] individual patent assignees (in terms of size of intellectual property portfolio).
  • Grants Analysis: An in-depth analysis of the grants received in the live cell encapsulation domain based on several factors such as [A] Year of Grant Award, [B] Amount Awarded, [C] Funding Institute Center, [D] Purpose of Grant Award, [E] Type of Grant Application and [F] Most Popular NIH Departments.
  • Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges in this domain.

Key Questions Answered in this Report

  • Which are the leading companies in the live cell encapsulation market?
  • Which region dominates the live cell encapsulation market?
  • What are the key trends observed in the live cell encapsulation market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by live cell encapsulation providers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Landscape
  • 5.2. Executive Summary: Market Trends
  • 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Overview of Cell Encapsulation
  • 6.2. Type of Encapsulation Materials
  • 6.3. Methods of Encapsulation
  • 6.4. Application Area of Cell Encapsulation
  • 6.5. Advantages of Cell Encapsulation Technologies
  • 6.6. Future Trends

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Live Cell Encapsulation Technologies: Overall Market Landscape
    • 7.2.1. Analysis by Type of Encapsulation Method
    • 7.2.2. Analysis by Route of Administration
    • 7.2.3. Analysis by Application Area
    • 7.2.4. Analysis by Type of Material Used
    • 7.2.5. Analysis by Therapeutic Area
    • 7.2.6. Analysis by Year of Establishment
    • 7.2.7. Analysis by Company Size
    • 7.2.8. Analysis by Location of Headquarters

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology and Key Parameters
  • 8.3.. Scoring Criteria
  • 8.4. Overview of Peer Groups
  • 8.5. Live Cell Encapsulation Technologies: Technology Competitiveness Analysis
    • 8.5.1. Live Cell Encapsulation Technologies: Provided by Players Headquartered in North America (Peer Group I)
      • 8.5.1.1. Live Cell Encapsulation Technologies: Overview of Players Providing Leading Technologies (Peer Group I)
    • 8.5.2. Live Cell Encapsulation Technologies: Provided by Players Headquartered in Europe (Peer Group II)
      • 8.5.2.1. Live Cell Encapsulation Technologies: Overview of Players Providing Leading Technologies (Peer Group II)
    • 8.5.3. Live Cell Encapsulation Technologies: Provided by Players Headquartered in Asia-Pacific and Rest of the World (Peer Group III)
      • 8.5.3.1. Live Cell Encapsulation Technologies: Overview of Players Providing Leading Technologies (Peer Group III)

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Algorae Pharmaceuticals
    • 9.2.1. Company Overview
    • 9.2.2. Technology Portfolio
    • 9.2.3. Recent Initiatives
  • Similar details are presented for other companies mentioned below (based on information in the public domain)
  • 9.3. Altucell
  • 9.4. Austrianova
  • 9.5. BIO INX
  • 9.6. Encellin
  • 9.7. Likarda
  • 9.8. Sphere Bio
  • 9.9. TreeFrog Therapeutics

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 16.2. Partnership Models
  • 16.3. Live Cell Encapsulation: List of Partnerships and Collaborations
    • 16.3.1. Analysis by Year of Partnership
    • 16.3.2. Analysis by Type of Partnership
    • 16.3.3. Analysis by Year and Type of Partnership
    • 16.3.4. Key Technology: Analysis by Number of Partnerships
    • 16.3.5. Key Therapeutic Area: Analysis by Number of Partnerships
    • 16.3.6. Most Active Players: Analysis by Number of Partnerships
  • 16.4. Analysis by Geography
    • 16.4.1. Local and International Agreements
    • 16.4.2. Intracontinental and Intercontinental Agreements

11. FUNDING AND INVESTMENTS

  • 11.1. Chapter Overview
  • 11.2. Funding Models
  • 11.3. Funding Lifecycle Analysis
  • 11.4. Investment Case: Risk and Returns
  • 11.5. Live Cell Encapsulation: List of Funding and Investments
    • 11.5.1 Analysis by Year of Investment
    • 11.5.2. Analysis by Type of Funding
    • 11.5.3. Analysis by Year of Investment and Type of Funding
    • 11.5.4. Analysis by Year of Amount Invested
    • 11.5.5. Analysis by Amount Invested and Type of Funding
    • 11.5.6. Analysis by Geography
    • 11.5.7. Most Active Players: Analysis by Number of Instances
    • 11.5.8. Most Active Players: Analysis by Amount Invested
    • 11.5.9. Most Active Investors: Analysis by Number of Instances
    • 11.5.10. Most Active Investors: Analysis by Number of Instances

12. PATENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Live Cell Encapsulation Market: Patent Analysis
    • 12.3.1. Analysis by Publication Year
    • 12.3.2. Analysis by Type of Patent
    • 12.3.3. Analysis by Type of Patent and Publication Year
    • 12.3.4. Analysis by Type of Applicant
    • 12.3.5. Analysis by Application Year
    • 12.3.6. Analysis by Patent Jurisdiction (Region)
    • 12.3.7. Analysis by Patent Jurisdiction (Country)
    • 12.3.8. Analysis by Patent Age
    • 12.3.9. Leading Industry Players: Analysis by Number of Patents
    • 12.3.10. Leading Non-Industry Players: Analysis by Number of Patents
    • 12.3.11. Leading Individual Assignees: Analysis by Number of Patents
    • 12.3.12. Analysis by CPC Symbols
  • 12.4. Live Cell Encapsulation: Patent Benchmarking Analysis
  • 12.5. Patent Valuation Analysis

13. GRANT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Types of Grants
  • 13.3. Types of Grants Applications
  • 13.4. Key Factors for Consideration
  • 13.5. Stages of Grants
  • 13.6. Methodology and Key Parameters
  • 13.7. Live Cell Encapsulation: Grants Analysis
    • 13.7.1. Analysis by Year of Grant Award
    • 13.7.2. Analysis by Amount Awarded
    • 13.7.3. Analysis by Funding Institute Center
    • 13.7.4. Analysis by Purpose of Grant Award
    • 13.7.5. Analysis by Type of Grant Application
    • 13.7.6. Analysis by Activity Code
    • 13.7.7. Analysis by Study Section Involved
    • 13.7.8. Analysis by Support Period
    • 13.7.9. Most Popular NIH Departments: Analysis by Number of Grants
    • 13.7.10. Type of Recipient Organizations: Analysis by Number of Grants
    • 13.7.11. Prominent Program Officers: Analysis by Number of Grants
    • 13.7.12. Popular Recipient Organizations: Analysis by Number of Grants
    • 13.7.13. Popular Recipient Organizations: Analysis by Grant Amount

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 14.1. Chapter Overview
  • 14.2. Market Drivers
  • 14.3. Market Restraints
  • 14.4. Market Opportunities
  • 14.5. Market Challenges
  • 14.6. Conclusion

15. GLOBAL LIVE CELL ENCAPSULATION MARKET

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035)
  • 15.4. Roots Analysis Perspective on Market Growth
  • 15.5. Scenario Analysis
    • 15.5.1. Conservative Scenario
    • 15.5.2. Optimistic Scenario
  • 15.6. Key Market Segmentations

16. LIVE CELL ENCAPSULATION MARKET, BY TYPE OF MANUFACTURING TECHNIQUE

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Live Cell Encapsulation Market: Distribution by Type of Manufacturing Technique
    • 16.3.1. Live Cell Encapsulation Market for Electrostatic Dripping, Forecasted Estimates (till 2035)
    • 16.3.2. Live Cell Encapsulation Market for Simple Dripping, Forecasted Estimates (till 2035)
    • 16.3.3. Live Cell Encapsulation Market for Coaxial Airflow, Forecasted Estimates (till 2035)
    • 16.3.4. Live Cell Encapsulation Market for Rotating Disk Atomization, Forecasted Estimates (till 2035)
    • 16.3.5. Live Cell Encapsulation Market for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
  • 16.4. Data Triangulation and Validation

17. LIVE CELL ENCAPSULATION MARKET, BY METHOD OF ENCAPSULATION

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Live Cell Encapsulation Market: Distribution by Method of Encapsulation
    • 17.3.1. Live Cell Encapsulation Market for Microencapsulation, Forecasted Estimates (till 2035)
    • 17.3.2. Live Cell Encapsulation Market for Microencapsulation, Forecasted Estimates (till 2035)
    • 17.3.3. Live Cell Encapsulation Market for Nanoencapsulation, Forecasted Estimates (till 2035)
  • 17.4. Data Triangulation and Validation

18. LIVE CELL ENCAPSULATION MARKET, BY TYPE OF ENCAPSULATION MATERIAL

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Live Cell Encapsulation Market: Distribution by Type of Encapsulation Material
    • 18.3.1. Live Cell Encapsulation Market for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
    • 18.3.2. Live Cell Encapsulation Market for Chitosan, Forecasted Estimates (till 2035)
    • 18.3.3. Live Cell Encapsulation Market for Medical-grade Plastics, Forecasted Estimates (till 2035)
    • 18.3.4. Live Cell Encapsulation Market for Silica, Forecasted Estimates (till 2035)
    • 18.3.5. Live Cell Encapsulation Market for Cellulose Hydrogels, Forecasted Estimates (till 2035)
    • 18.3.6. Live Cell Encapsulation Market for Red Blood Cells, Forecasted Estimates (till 2035)
  • 18.4. Data Triangulation and Validation

19. LIVE CELL ENCAPSULATION MARKET, BY APPLICATION AREA

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Live Cell Encapsulation Market: Distribution by Application Area
    • 19.3.1. Live Cell Encapsulation Market for Drug Delivery, Forecasted Estimates (till 2035)
    • 19.3.2. Live Cell Encapsulation Market for Immune Protection, Forecasted Estimates (till 2035)
    • 19.3.3. Live Cell Encapsulation Market for Probiotics and Functional Food, Forecasted Estimates (till 2035)
    • 19.3.4. Live Cell Encapsulation Market for Others, Forecasted Estimates (till 2035)
  • 19.4. Data Triangulation and Validation

20. LIVE CELL ENCAPSULATION MARKET, BY THERAPEUTIC AREA

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Live Cell Encapsulation Market: Distribution by Therapeutic Area
    • 20.3.1. Live Cell Encapsulation Market for Metabolic Disorders, Forecasted Estimates (till 2035)
    • 20.3.2. Live Cell Encapsulation Market for Oncological Disorders, Forecasted Estimates (till 2035)
    • 20.3.3. Live Cell Encapsulation Market for Neurological Disorders, Forecasted Estimates (till 2035)
    • 20.3.4. Live Cell Encapsulation Market for Ophthalmic Disorders, Forecasted Estimates (till 2035)
    • 20.3.5. Live Cell Encapsulation Market for Cardiovascular Disorders, Forecasted Estimates (till 2035)
    • 20.3.6. Live Cell Encapsulation Market for Nephrological Disorders, Forecasted Estimates (till 2035)
    • 20.3.7. Live Cell Encapsulation Market for Other Disorders, Forecasted Estimates (till 2035)
  • 20.4. Data Triangulation and Validation

21. LIVE CELL ENCAPSULATION MARKET, BY TYPE OF PAYMENT

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Live Cell Encapsulation Market: Distribution by Type of Payment
    • 21.3.1. Live Cell Encapsulation Market for Milestone Payments, Forecasted Estimates (till 2035)
    • 21.3.2. Live Cell Encapsulation Market for Upfront Payments, Forecasted Estimates (till 2035)
  • 21.4. Data Triangulation and Validation

22. LIVE CELL ENCAPSULATION MARKET, BY GEOGRAPHY

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Live Cell Encapsulation Market: Distribution by Geography
    • 22.3.1. Antibody Contract Manufacturing Market in North America: Forecasted Estimates (till 2035)
      • 22.3.1.1. Antibody Contract Manufacturing Market in the US: Forecasted Estimates (till 2035)
      • 22.3.1.2. Antibody Contract Manufacturing Market in Canada: Forecasted Estimates (till 2035)
    • 22.3.2. Antibody Contract Manufacturing Market in Europe: Forecasted Estimates (till 2035)
      • 22.3.2.1. Antibody Contract Manufacturing Market in France: Forecasted Estimates (till 2035)
      • 22.3.2.2. Antibody Contract Manufacturing Market in Netherlands: Forecasted Estimates (till 2035)
      • 22.3.2.3. Antibody Contract Manufacturing Market in the UK: Forecasted Estimates (till 2035)
      • 22.3.2.4. Antibody Contract Manufacturing Market in Belgium: Forecasted Estimates (till 2035)
    • 22.3.3. Antibody Contract Manufacturing Market in Asia-Pacific: Forecasted Estimates (till 2035)
      • 22.3.3.1. Antibody Contract Manufacturing Market in Japan: Forecasted Estimates (till 2035)
      • 22.3.3.2. Antibody Contract Manufacturing Market in Singapore: Forecasted Estimates (till 2035)
  • 22.4. Market Dynamics Assessment
    • 22.4.1. Penetration-Growth (P-G) Matrix
  • 22.5. Data Triangulation and Validation

23. LIVE CELL ENCAPSULATION MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

  • 23.1. Live Cell Encapsulation Market in North America: Distribution by Type of Manufacturing Technique
    • 23.1.1. Live Cell Encapsulation Market in North America for Electrostatic Dripping, Forecasted Estimates (till 2035)
    • 23.1.2. Live Cell Encapsulation Market in North America for Simple Dripping, Forecasted Estimates (till 2035)
    • 23.1.3. Live Cell Encapsulation Market in North America for Coaxial Airflow, Forecasted Estimates (till 2035)
    • 23.1.4. Live Cell Encapsulation Market in North America for Rotating Disk Atomization, Forecasted Estimates (till 2035)
    • 23.1.5. Live Cell Encapsulation Market in North America for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
  • 23.2. Live Cell Encapsulation Market in North America: Distribution by Method of Encapsulation
    • 23.2.1. Live Cell Encapsulation Market in North America for Microencapsulation, Forecasted Estimates (till 2035)
    • 23.2.2. Live Cell Encapsulation Market in North America for Macroencapsulation, Forecasted Estimates (till 2035)
    • 23.2.3. Live Cell Encapsulation Market in North America for Nanoencapsulation, Forecasted Estimates (till 2035)
  • 23.3. Live Cell Encapsulation Market in North America: Distribution by Encapsulation Material
    • 23.3.1. Live Cell Encapsulation Market in North America for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
    • 23.3.2. Live Cell Encapsulation Market in North America for Chitosan, Forecasted Estimates (till 2035)
    • 23.3.3. Live Cell Encapsulation Market in North America for Medica-grade Plastics, Forecasted Estimates (till 2035)
    • 23.3.4. Live Cell Encapsulation Market in North America for Silica, Forecasted Estimates (till 2035)
    • 23.3.5. Live Cell Encapsulation Market in North America for Cellulose Hydrogels, Forecasted Estimates (till 2035)
    • 23.3.6. Live Cell Encapsulation Market in North America for Red Blood Cells, Forecasted Estimates (till 2035)
  • 23.4. Live Cell Encapsulation Market in North America: Distribution by Application Area
    • 23.4.1. Live Cell Encapsulation Market in North America for Drug Delivery, Forecasted Estimates (till 2035)
    • 23.4.2. Live Cell Encapsulation Market in North America for Immune Protection, Forecasted Estimates (till 2035)
    • 23.4.3. Live Cell Encapsulation Market in North America for Probiotics and Functional Food, Forecasted Estimates (till 2035)
    • 23.4.4. Live Cell Encapsulation Market in North America for Others, Forecasted Estimates (till 2035)
  • 23.5. Live Cell Encapsulation Market in North America: Distribution by Therapeutic Area
    • 23.5.1. Live Cell Encapsulation Market in North America for Metabolic Disorders, Forecasted Estimates (till 2035)
    • 23.5.2. Live Cell Encapsulation Market in North America for Oncological Disorders, Forecasted Estimates (till 2035)
    • 23.5.3. Live Cell Encapsulation Market in North America for Neurological Disorders, Forecasted Estimates (till 2035)
    • 23.5.4. Live Cell Encapsulation Market in North America for Ophthalmic Disorders, Forecasted Estimates (till 2035)
    • 23.5.5. Live Cell Encapsulation Market in North America for Cardiovascular Disorders, Forecasted Estimates (till 2035)
    • 23.5.6. Live Cell Encapsulation Market in North America for Nephrological Disorders, Forecasted Estimates (till 2035)
  • 23.6. Live Cell Encapsulation Market in North America: Distribution by Type of Payment
    • 23.6.1. Live Cell Encapsulation Market in North America for Milestone Payments, Forecasted Estimates (till 2035)
    • 23.6.2. Live Cell Encapsulation Market in North America for Upfront Payments, Forecasted Estimates (till 2035)

24. LIVE CELL ENCAPSULATION MARKET OPPORTUNITY ANALYSIS: EUROPE

  • 24.1. Live Cell Encapsulation Market in Europe: Distribution by Type of Manufacturing Technique
    • 24.1.1. Live Cell Encapsulation Market in Europe for Electrostatic Dripping, Forecasted Estimates (till 2035)
    • 24.1.2. Live Cell Encapsulation Market in Europe for Simple Dripping, Forecasted Estimates (till 2035)
    • 24.1.3. Live Cell Encapsulation Market in Europe for Coaxial Airflow, Forecasted Estimates (till 2035)
    • 24.1.4. Live Cell Encapsulation Market in Europe for Rotating Disk Atomization, Forecasted Estimates (till 2035)
    • 24.1.5. Live Cell Encapsulation Market in Europe for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
  • 24.2. Live Cell Encapsulation Market in Europe: Distribution by Method of Encapsulation
    • 24.2.1. Live Cell Encapsulation Market in Europe for Microencapsulation, Forecasted Estimates (till 2035)
    • 24.2.2. Live Cell Encapsulation Market in Europe for Macroencapsulation, Forecasted Estimates (till 2035)
    • 24.2.3. Live Cell Encapsulation Market in Europe for Nanoencapsulation, Forecasted Estimates (till 2035)
  • 24.3. Live Cell Encapsulation Market in Europe: Distribution by Encapsulation Material
    • 24.3.1. Live Cell Encapsulation Market in Europe for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
    • 24.3.2. Live Cell Encapsulation Market in Europe for Chitosan, Forecasted Estimates (till 2035)
    • 24.3.3. Live Cell Encapsulation Market in Europe for Medica-grade Plastics, Forecasted Estimates (till 2035)
    • 24.3.4. Live Cell Encapsulation Market in Europe for Silica, Forecasted Estimates (till 2035)
    • 24.3.5. Live Cell Encapsulation Market in Europe for Cellulose Hydrogels, Forecasted Estimates (till 2035)
    • 24.3.6. Live Cell Encapsulation Market in Europe for Red Blood Cells, Forecasted Estimates (till 2035)
  • 24.4. Live Cell Encapsulation Market in Europe: Distribution by Application Area
    • 24.4.1. Live Cell Encapsulation Market in Europe for Drug Delivery, Forecasted Estimates (till 2035)
    • 24.4.2. Live Cell Encapsulation Market in Europe for Immune Protection, Forecasted Estimates (till 2035)
    • 24.4.3. Live Cell Encapsulation Market in Europe for Probiotics and Functional Food, Forecasted Estimates (till 2035)
    • 24.4.4. Live Cell Encapsulation Market in Europe for Others, Forecasted Estimates (till 2035)
  • 24.5. Live Cell Encapsulation Market in Europe: Distribution by Therapeutic Area
    • 24.5.1. Live Cell Encapsulation Market in Europe for Metabolic Disorders, Forecasted Estimates (till 2035)
    • 24.5.2. Live Cell Encapsulation Market in Europe for Oncological Disorders, Forecasted Estimates (till 2035)
    • 24.5.3. Live Cell Encapsulation Market in Europe for Neurological Disorders, Forecasted Estimates (till 2035)
    • 24.5.4. Live Cell Encapsulation Market in Europe for Ophthalmic Disorders, Forecasted Estimates (till 2035)
    • 24.5.5. Live Cell Encapsulation Market in Europe for Cardiovascular Disorders, Forecasted Estimates (till 2035)
    • 24.5.6. Live Cell Encapsulation Market in Europe for Nephrological Disorders, Forecasted Estimates (till 2035)
  • 24.6. Live Cell Encapsulation Market in Europe: Distribution by Type of Payment
    • 24.6.1. Live Cell Encapsulation Market in Europe for Milestone Payments, Forecasted Estimates (till 2035)
    • 24.6.2. Live Cell Encapsulation Market in Europe for Upfront Payments, Forecasted Estimates (till 2035)

25. LIVE CELL ENCAPSULATION MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

  • 25.1. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Type of Manufacturing Technique
    • 25.1.1. Live Cell Encapsulation Market in Asia-Pacific for Electrostatic Dripping, Forecasted Estimates (till 2035)
    • 25.1.2. Live Cell Encapsulation Market in Asia-Pacific for Simple Dripping, Forecasted Estimates (till 2035)
    • 25.1.3. Live Cell Encapsulation Market in Asia-Pacific for Coaxial Airflow, Forecasted Estimates (till 2035)
    • 25.1.4. Live Cell Encapsulation Market in Asia-Pacific for Rotating Disk Atomization, Forecasted Estimates (till 2035)
    • 25.1.5. Live Cell Encapsulation Market in Asia-Pacific for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
  • 25.2. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Method of Encapsulation
    • 25.2.1. Live Cell Encapsulation Market in Asia-Pacific for Microencapsulation, Forecasted Estimates (till 2035)
    • 25.2.2. Live Cell Encapsulation Market in Asia-Pacific for Macroencapsulation, Forecasted Estimates (till 2035)
    • 25.2.3. Live Cell Encapsulation Market in Asia-Pacific for Nanoencapsulation, Forecasted Estimates (till 2035)
  • 25.3. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Encapsulation Material
    • 25.3.1. Live Cell Encapsulation Market in Asia-Pacific for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
    • 25.3.2. Live Cell Encapsulation Market in Asia-Pacific for Chitosan, Forecasted Estimates (till 2035)
    • 25.3.3. Live Cell Encapsulation Market in Asia-Pacific for Medica-grade Plastics, Forecasted Estimates (till 2035)
    • 25.3.4. Live Cell Encapsulation Market in Asia-Pacific for Silica, Forecasted Estimates (till 2035)
    • 25.3.5. Live Cell Encapsulation Market in Asia-Pacific for Cellulose Hydrogels, Forecasted Estimates (till 2035)
    • 25.3.6. Live Cell Encapsulation Market in Asia-Pacific for Red Blood Cells, Forecasted Estimates (till 2035)
  • 25.4. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Application Area
    • 25.4.1. Live Cell Encapsulation Market in Asia-Pacific for Drug Delivery, Forecasted Estimates (till 2035)
    • 25.4.2. Live Cell Encapsulation Market in Asia-Pacific for Immune Protection, Forecasted Estimates (till 2035)
    • 25.4.3. Live Cell Encapsulation Market in Asia-Pacific for Probiotics and Functional Food, Forecasted Estimates (till 2035)
    • 25.4.4. Live Cell Encapsulation Market in Asia-Pacific for Others, Forecasted Estimates (till 2035)
  • 25.5. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Therapeutic Area
    • 25.5.1. Live Cell Encapsulation Market in Asia-Pacific for Metabolic Disorders, Forecasted Estimates (till 2035)
    • 25.5.2. Live Cell Encapsulation Market in Asia-Pacific for Oncological Disorders, Forecasted Estimates (till 2035)
    • 25.5.3. Live Cell Encapsulation Market in Asia-Pacific for Neurological Disorders, Forecasted Estimates (till 2035)
    • 25.5.4. Live Cell Encapsulation Market in Asia-Pacific for Ophthalmic Disorders, Forecasted Estimates (till 2035)
    • 25.5.5. Live Cell Encapsulation Market in Asia-Pacific for Cardiovascular Disorders, Forecasted Estimates (till 2035)
    • 25.5.6. Live Cell Encapsulation Market in Asia-Pacific for Nephrological Disorders, Forecasted Estimates (till 2035)
  • 25.6. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Type of Payment
    • 25.6.1. Live Cell Encapsulation Market in Asia-Pacific for Milestone Payments, Forecasted Estimates (till 2035)
    • 25.6.2. Live Cell Encapsulation Market in Asia-Pacific for Upfront Payments, Forecasted Estimates (till 2035)
  • *Detailed information on Chapters 25-27 is available in the Excel Data Packs shared along with the report**

26. PORTER'S FIVE FORCES

  • 26.1. Chapter Overview
  • 26.2. Methodology and Assumptions
  • 26.3. Key Parameters
    • 26.3.1. Threat of New Entrants
    • 26.3.2. Bargaining Power of Buyers
    • 26.3.3. Bargaining Power of Service Providers
    • 26.3.4. Threats of Substitute Products
    • 26.3.5. Rivalry Among Existing Competitors
  • 26.4. Concluding Remarks

27. CONCLUDING REMARKS

28. EXECUTIVE INSIGHTS

29. APPENDIX I: TABULATED DATA

30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 Live Cell Encapsulation Market: List of Live Cell Encapsulation Technologies
  • Table 7.2 Live Cell Encapsulation Market: List of Live Cell Encapsulation Technology Providers
  • Table 10.1 Live Cell Encapsulation Market: List of Live Cell Encapsulation Partnerships and Collaborations, Since 2018
  • Table 11.1 Live Cell Encapsulation Market: List of Live Cell Encapsulation Funding and Investments, Since 2021
  • Table 12.1 Live Cell Encapsulation Market: List of Patents Published, Since 2020
  • Table 13.1 Live Cell Encapsulation Market: List of Grants, Till 2025
  • Table 29.1 Live Cell Encapsulation Technologies: Distribution by Type of Encapsulation Method
  • Table 29.2 Live Cell Encapsulation Technologies: Distribution by Route of Administration
  • Table 29.3 Live Cell Encapsulation Technologies: Distribution by Application Area
  • Table 29.4 Live Cell Encapsulation Technologies: Distribution by Type of Material Used
  • Table 29.5 Live Cell Encapsulation Technologies: Distribution by Therapeutic Area
  • Table 29.6 Live Cell Encapsulation Technology Providers: Distribution by Year of Establishment
  • Table 29.7 Live Cell Encapsulation Technology Providers: Distribution by Company Size
  • Table 29.8 Live Cell Encapsulation Technology Providers: Distribution by Location of Headquarters
  • Table 29.9 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2018
  • Table 29.10 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 29.11 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2018
  • Table 29.12 Key Technology: Distribution by Number of Partnerships
  • Table 29.13 Key Therapeutic Area: Distribution by Number of Partnerships
  • Table 29.14 Most Active Players: Distribution by Number of Partnerships
  • Table 29.15 Partnerships and Collaborations: Local and International Agreements
  • Table 29.16 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 29.17 Funding and Investments: Cumulative Year-wise Trend, Since 2021
  • Table 29.18 Funding and Investments: Distribution by Type of Funding
  • Table 29.19 Funding and Investments: Distribution by Year and Type of Funding, Since 2021
  • Table 29.20 Funding and Investments: Cumulative Amount Invested by Year, Since 2021 (USD Million)
  • Table 29.21 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
  • Table 29.22 Funding and Investments : Distribution by Geography
  • Table 29.23 Most Active Players: Distribution by Number of Instances
  • Table 29.24 Most Active Players: Distribution by Amount Invested
  • Table 29.25 Most Active Investors: Distribution by Number of Instances
  • Table 29.26 Key Technologies: Distribution by Number of Instances
  • Table 29.27 Patent Analysis: Distribution by Patent Publication Year
  • Table 29.28 Patent Analysis: Distribution by Type of Patent
  • Table 29.29 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year, Since 2020
  • Table 29.30 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant, Since 2020
  • Table 29.31 Patent Analysis: Distribution by Patent Application Year
  • Table 29.32 Patent Analysis: Distribution by Patent Jurisdiction (Region)
  • Table 29.33 Patent Analysis: Distribution by Patent Jurisdiction (Country)
  • Table 29.34 Patent Analysis: Distribution by Patent Age
  • Table 29.35 Leading Industry Players: Distribution by Number of Patents
  • Table 29.36 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 29.37 Leading Patent Assignees: Distribution by Number of Patents
  • Table 29.38 Grants Analysis: Cumulative Year-wise Trend, Since 2020
  • Table 29.39 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
  • Table 29.40 Grants Analysis: Distribution by Funding Institute Center
  • Table 29.41 Grants Analysis: Distribution by Purpose of Grant Award
  • Table 29.42 Grants Analysis: Distribution by Type of Grant Application
  • Table 29.43 Grants Analysis: Distribution by Activity Code
  • Table 29.44 Grants Analysis: Distribution by Study Section Involved
  • Table 29.45 Grants Analysis: Distribution by Support Period
  • Table 29.46 Most Popular NIH Departments: Distribution by Number of Grants
  • Table 29.47 Type of Recipient Organizations: Distribution by Number of Grants
  • Table 29.48 Prominent Program Officers: Distribution by Number of Grants
  • Table 29.49 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 29.50 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Table 29.51 Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035): Base Scenario (USD Million)
  • Table 29.52 Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
  • Table 29.53 Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
  • Table 29.54 Live Cell Encapsulation Market: Distribution by Type of Manufacturing Technique
  • Table 29.55 Live Cell Encapsulation Market for Electrostatic Dripping, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.56 Live Cell Encapsulation Market for Simple Dripping, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.57 Live Cell Encapsulation Market for Coaxial Airflow, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.58 Live Cell Encapsulation Market for Rotating Disk Atomization, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.59 Live Cell Encapsulation Market for Other Manufacturing Techniques, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.60 Live Cell Encapsulation Market: Distribution by Method of Encapsulation
  • Table 29.61 Live Cell Encapsulation Market for Microencapsulation, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.62 Live Cell Encapsulation Market for Macroencapsulation, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.63 Live Cell Encapsulation Market for Nanoencapsulation, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.64 Live Cell Encapsulation Market: Distribution by Type of Encapsulation Material
  • Table 29.65 Live Cell Encapsulation Market for Alginate-based Microcapsules, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.66 Live Cell Encapsulation Market for Chitosan, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.67 Live Cell Encapsulation Market for Medical-grade Plastics, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.68 Live Cell Encapsulation Market for Silica, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.69 Live Cell Encapsulation Market for Cellulose Hydrogels, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.70 Live Cell Encapsulation Market for Red Blood Cells, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.71 Live Cell Encapsulation Market: Distribution by Type of Application Area
  • Table 29.72 Live Cell Encapsulation Market for Drug Delivery, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.73 Live Cell Encapsulation Market for Immune Protection, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.74 Live Cell Encapsulation Market for Probiotics and Functional Food, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.75 Live Cell Encapsulation Market for Others, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.76 Live Cell Encapsulation Market: Distribution by Type of Therapeutic Area
  • Table 29.77 Live Cell Encapsulation Market for Metabolic Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.78 Live Cell Encapsulation Market for Oncological Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.79 Live Cell Encapsulation Market for Neurological Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.80 Live Cell Encapsulation Market for Ophthalmic Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.81 Live Cell Encapsulation Market for Cardiovascular Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.82 Live Cell Encapsulation Market for Nephrological Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.83 Live Cell Encapsulation Market for Other Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.84 Live Cell Encapsulation Market: Distribution by Type of Payment
  • Table 29.85 Live Cell Encapsulation Market for Milestone Payment, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.86 Live Cell Encapsulation Market for Upfront Payment, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.87 Live Cell Encapsulation Market: Distribution by Geography
  • Table 29.88 Live Cell Encapsulation Market in North America, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.89 Live Cell Encapsulation Market in the US, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.90 Live Cell Encapsulation Market in Canada, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.91 Live Cell Encapsulation Market in Europe, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.92 Live Cell Encapsulation Market in France, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.93 Live Cell Encapsulation Market in Netherlands, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.94 Live Cell Encapsulation Market in the UK, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.95 Live Cell Encapsulation Market in Belgium, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.96 Live Cell Encapsulation Market in Asia-Pacific, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.97 Live Cell Encapsulation Market in Japan, Forecasted Estimates (till 2035) (USD Million)
  • Table 29.98 Live Cell Encapsulation Market in Singapore, Forecasted Estimates (till 2035) (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Key Market Segmentation
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Overall Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 7.1 Live Cell Encapsulation Technologies: Distribution by Type of Encapsulation Method
  • Figure 7.2 Live Cell Encapsulation Technologies: Distribution by Route of Administration
  • Figure 7.3 Live Cell Encapsulation Technologies: Distribution by Application Area
  • Figure 7.4 Live Cell Encapsulation Technologies: Distribution by Type of Material Used
  • Figure 7.5 Live Cell Encapsulation Technologies: Distribution by Therapeutic Area
  • Figure 7.6 Live Cell Encapsulation Technology Providers: Distribution by Year of Establishment
  • Figure 7.7 Live Cell Encapsulation Technology Providers: Distribution by Company Size
  • Figure 7.8 Live Cell Encapsulation Technology Providers: Distribution by Location of Headquarters
  • Figure 8.1 Technology Competitiveness Analysis: Live Cell Encapsulation Technologies Provided by Players Headquartered in North America (Peer Group I)
  • Figure 8.2 Technology Competitiveness Analysis: Live Cell Encapsulation Technologies Provided by Players Headquartered in Europe (Peer Group II)
  • Figure 8.3 Technology Competitiveness Analysis: Live Cell Encapsulation Technologies Provided by Players Headquartered in Asia-Pacific (Peer Group III)
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2018
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2018
  • Figure 10.4 Key Technology: Distribution by Number of Partnerships
  • Figure 10.5 Key Therapeutic Area: Distribution by Number of Partnerships
  • Figure 10.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 10.7 Partnerships and Collaborations: Local and International Agreements
  • Figure 10.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 11.1 Funding and Investments: Cumulative Year-wise Trend, Since 2021
  • Figure 11.2 Funding and Investments: Distribution by Type of Funding
  • Figure 11.3 Funding and Investments: Distribution by Year and Type of Funding, Since 2021
  • Figure 11.4 Funding and Investments: Cumulative Amount Invested by Year, Since 2021 (USD Million)
  • Figure 11.5 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
  • Figure 11.6 Funding and Investments : Distribution by Geography
  • Figure 11.7 Most Active Players: Distribution by Number of Instances
  • Figure 11.8 Most Active Players: Distribution by Amount Invested
  • Figure 11.9 Most Active Investors: Distribution by Number of Instances
  • Figure 11.10 Key Technologies: Distribution by Number of Instances
  • Figure 12.1 Patent Analysis: Distribution by Patent Publication Year
  • Figure 12.2 Patent Analysis: Distribution by Type of Patent
  • Figure 12.3 Patent Analysis: Distribution by Type of Patent and Publication Year
  • Figure 12.4 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Figure 12.5 Patent Analysis: Distribution by Patent Application Year
  • Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Region)
  • Figure 12.7 Patent Analysis: Distribution by Patent Jurisdiction (Country)
  • Figure 12.9 Patent Analysis: Distribution by Patent Age
  • Figure 12.9 Leading Industry Players: Distribution by Number of Patents
  • Figure 12.10 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 12.11 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 12.12 Patent Analysis: Distribution by CPC Symbols
  • Figure 12.13 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 12.14 Live Cell Encapsulation Technologies: Patent Valuation
  • Figure 13.1 Grants Analysis: Cumulative Year-wise Trend, Since 2020
  • Figure 13.2 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
  • Figure 13.3 Grants Analysis: Distribution by Funding Institute Center
  • Figure 13.4 Grants Analysis: Distribution by Purpose of Grant Award
  • Figure 13.5 Grants Analysis: Distribution by Type of Grant Application
  • Figure 13.6 Grants Analysis: Distribution by Activity Code
  • Figure 13.7 Grants Analysis: Distribution by Study Section Involved
  • Figure 13.8 Grants Analysis: Distribution by Support Period
  • Figure 13.9 Most Popular NIH Departments: Distribution by Number of Grants
  • Figure 13.10 Type of Recipient Organizations: Distribution by Number of Grants
  • Figure 13.11 Prominent Program Officers: Distribution by Number of Grants
  • Figure 13.12 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 12.13 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Figure 15.1 Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035): Base Scenario (USD Million)
  • Figure 15.2 Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
  • Figure 15.3 Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
  • Figure 16.1 Live Cell Encapsulation Market: Distribution by Type of Manufacturing Technique
  • Figure 16.2 Live Cell Encapsulation Market for Electrostatic Dripping, Forecasted Estimates (till 2035) (USD Million)
  • Figure 16.3 Live Cell Encapsulation Market for Simple Dripping, Forecasted Estimates (till 2035) (USD Million)
  • Figure 16.4 Live Cell Encapsulation Market for Coaxial Airflow, Forecasted Estimates (till 2035) (USD Million)
  • Figure 16.5 Live Cell Encapsulation Market for Rotating Disk Atomization, Forecasted Estimates (till 2035) (USD Million)
  • Figure 16.6 Live Cell Encapsulation Market for Other Manufacturing Techniques, Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.1 Live Cell Encapsulation Market: Distribution by Method of Encapsulation
  • Figure 17.2 Live Cell Encapsulation Market for Microencapsulation, Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.3 Live Cell Encapsulation Market for Macroencapsulation, Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.4 Live Cell Encapsulation Market for Nanoencapsulation, Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.1 Live Cell Encapsulation Market: Distribution by Type of Encapsulation Material
  • Figure 18.2 Live Cell Encapsulation Market for Alginate-based Microcapsules, Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.3 Live Cell Encapsulation Market for Chitosan, Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.4 Live Cell Encapsulation Market for Medical-grade Plastics, Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.5 Live Cell Encapsulation Market for Silica, Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.6 Live Cell Encapsulation Market for Cellulose Hydrogels, Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.7 Live Cell Encapsulation Market for Red Blood Cells, Forecasted Estimates (till 2035) (USD Million)
  • Figure 19.1 Live Cell Encapsulation Market: Distribution by Type of Application Area
  • Figure 19.2 Live Cell Encapsulation Market for Drug Delivery, Forecasted Estimates (till 2035) (USD Million)
  • Figure 19.3 Live Cell Encapsulation Market for Immune Protection, Forecasted Estimates (till 2035) (USD Million)
  • Figure 19.4 Live Cell Encapsulation Market for Probiotics and Functional Food, Forecasted Estimates (till 2035) (USD Million)
  • Figure 19.5 Live Cell Encapsulation Market for Others, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.1 Live Cell Encapsulation Market: Distribution by Type of Therapeutic Area
  • Figure 20.2 Live Cell Encapsulation Market for Metabolic Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.3 Live Cell Encapsulation Market for Oncological Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.4 Live Cell Encapsulation Market for Neurological Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.5 Live Cell Encapsulation Market for Ophthalmic Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.6 Live Cell Encapsulation Market for Cardiovascular Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.7 Live Cell Encapsulation Market for Nephrological Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 20.8 Live Cell Encapsulation Market for Other Disorders, Forecasted Estimates (till 2035) (USD Million)
  • Figure 21.1 Live Cell Encapsulation Market: Distribution by Type of Payment
  • Figure 21.2 Live Cell Encapsulation Market for Milestone Payment, Forecasted Estimates (till 2035) (USD Million)
  • Figure 21.3 Live Cell Encapsulation Market for Upfront Payment, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.1 Live Cell Encapsulation Market: Distribution by Geography
  • Figure 22.2 Live Cell Encapsulation Market in North America, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.3 Live Cell Encapsulation Market in the US, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.4 Live Cell Encapsulation Market in Canada, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.5 Live Cell Encapsulation Market in Europe, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.6 Live Cell Encapsulation Market in France, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.7 Live Cell Encapsulation Market in Netherlands, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.8 Live Cell Encapsulation Market in the UK, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.9 Live Cell Encapsulation Market in Belgium, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.10 Live Cell Encapsulation Market in Asia-Pacific, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.11 Live Cell Encapsulation Market in Japan, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.12 Live Cell Encapsulation Market in Singapore, Forecasted Estimates (till 2035) (USD Million)
  • Figure 22.13 Penetration Growth (P-G) Matrix: Key Geographical Regions